LIFECORE BIOMEDICAL, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
LIFECORE BIOMEDICAL, INC. (LFCR) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $353.00 thousand for the 12-month period ending 2015-05-31, per its 10-K filed 2015-07-31.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2015-07-31
- LIFECORE BIOMEDICAL, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $353.00K, a 256.57% increase from fiscal 2014.
- LIFECORE BIOMEDICAL, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was $99.00K, a 72.80% decline from fiscal 2013.
- LIFECORE BIOMEDICAL, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $364.00K.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2015-05-31 | $353.00K 10-K · filed 2015-07-31 |
| 2014-05-25 | $99.00K 10-K · filed 2014-08-01 |
| 2013-05-26 | $364.00K 10-K · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |